retatrutide glp-1 gip glucagon agonist Synedica Buy Retatrutide Research Peptide |

In October 2024, the FDA announced that the shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, was resolved, and shortages of other GLP-1s are also poised to be resolved in the near future

The weight loss was a fortuitous side effect because semaglutide was originally designed to be a treatment for diabetes

Severe Gastrointestinal Disorders and GLP-1 Safety Patients with a history of pancreatitis face increased risk on GLP-1 therapy

[13] [1] Approved in November 2023, Zepbound represents a novel therapeutic approach to weight loss through its unique dual-receptor mechanism of action

The reduced availability of these medications, combined with their high cost, has led many patients to seek alternative ways to obtain them, including compounded medications that may not offer the same potency or safety profile as approved drugs

However, not enough private insurers were willing to participate, so instead CMS is running an 18-month demonstration project (Bridge), where the obesity drugs are covered directly by the taxpayers and future Medicare premiums